Market

Biopharmaceutical Contract Manufacturing Market to Surge by 2032
Management & Regulatory Biopharmaceutical Contract Manufacturing Market to Surge by 2032

The global biopharmaceutical contract manufacturing market is anticipated to experience significant growth from 2024 to 2032. This market's expansion is driven by continuous technological innovations, increased research and development (R&D) investments, and strategic collaborations among

Biotech Investment Opportunities Beyond Popular GLP-1 Weight-Loss Drugs
Management & Regulatory Biotech Investment Opportunities Beyond Popular GLP-1 Weight-Loss Drugs

The biotech sector is brimming with opportunities that extend far beyond the much-talked-about GLP-1 weight-loss drugs, which have garnered significant attention following the 2024 European Association for the Study of Diabetes (EASD) meeting. While GLP-1 treatments, led by giants like Eli Lilly

Global Trends in Biopharma Venture Capital: Growth and Caution
Management & Regulatory Global Trends in Biopharma Venture Capital: Growth and Caution

The biopharma sector has experienced a roller coaster of venture capital investments over the past decade and a half. From explosive growth driven by the COVID-19 pandemic to a more selective and strategic investment environment, the landscape continues to evolve rapidly. This article will delve

Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence
Management & Regulatory Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence

Jason Raleigh Purchases $15M in Zenas BioPharma Stock, Boosts Confidence In a remarkable display of confidence, Jason Raleigh, a director at Zenas BioPharma, Inc. (NASDAQ: ZBIO), has made a substantial investment in the company by acquiring $15 million worth of stock. This blockbuster move not only

Are Zenas Biopharma and Biren Technology Leading the IPO Market Revival?
Management & Regulatory Are Zenas Biopharma and Biren Technology Leading the IPO Market Revival?

The IPO market has faced significant turmoil over the past few years, with many companies postponing or canceling their public offering plans due to weak market conditions. However, recent developments indicate a promising shift. Companies like Zenas Biopharma and Biren Technology are making

How Is Novartis Transforming Radiopharma Production in the U.S.?
Management & Regulatory How Is Novartis Transforming Radiopharma Production in the U.S.?

Enhancing Manufacturing Capabilities Novartis is making significant strides in its efforts to expand manufacturing capabilities to meet the growing demand for radiopharmaceutical therapies aimed at treating cancer. To achieve this, the company is not only expanding an existing facility in

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later